Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:03:01.095Z.
Calculation as of: 2026-10-06T19:03:01.095Z.
Quote observation: 2026-10-06T18:59:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca628ff6f55b6345e2cefca22780bd34dfabddebf8a5c62bf0c86d2d29f40561
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$11.12M
EV/EBIT Ratio
N/A
TTM Avg
13.02x
3Y Avg
13.02x
5Y Avg
13.02x
Market Cap
$12.12M
EV/EBIT Ratio
N/A
TTM Avg
1095.87x
3Y Avg
388.61x
5Y Avg
279.45x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | $11.53M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.92M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.25M | N/A | N/A | N/A | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.22M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A | 13.02x | 13.02x | 13.02x |
| BioVie Inc. (BIVI)vs › | $11.09M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.08M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.13M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 1095.87x | 388.61x | 279.45x |
| Caring Brands, Inc. (CABR)vs › | $10.82M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
